NIH Proteomics Interest Group

Link to Upcoming Meetings

Link to Meeting Archives

Link to Related Links

Link to NIH Labs

Link Fellows Forum Info

Link to Join SIG


ProtIG is an NIH Special Interest Group (SIG) that organizes seminars and workshops in relevant areas of proteomics, including talks on separation and protein identification methods, determination of post-translational modifications, protein-protein interactions, and bioinformatics and data management. A monthly seminar series is usually held at 11am on the first Wednesday of each month (always check the Mtgs/Seminars button on this page for these and other PROTIG announced meetings). To receive email announcements of ProtIG events, join the listserv (Join the SIG button on this page)

April ProtIG Seminar
Please note the time and location
April 5th, 2018
9:30 am - 10:30am
Building 50, NIH Campus
Room 1328/1334 (Rear Lobby Conference Room)
Michael Brad Strader, Ph. D.
Staff Scientist
Laboratory of Biochemistry and Vascular Biology
Center for Biologics Evaluation and Research, FDA

"Analysis of RBC Derived Microparticles from Sickle Cell Mice using Mass Spectrometry: The Impact of Sickle Cell Disease Induced Oxidative Stress on MP Proteome"

Polymerization of sickle cell hemoglobin S (HbS) is recognized as a key event in the pathophysiology of sickle cell disease (SCD). Repeated HbS polymerization promotes an altered red blood cell (RBC) membrane, hemolysis, and microparticles (MP) formation, which have been shown to play a significant role in the interaction of RBCs with vascular endothelium and progression of vaso-occlusive events. We have recently reported that free HbS oxidizes faster, remains locked in a highly oxidizing form (ferryl) longer and loses heme faster than normal HbA. The first part of this seminar will focus on the Laboratory of Biochemistry and Vascular Biology’s (LBVB) objectives, strategy and workflow for characterizing the RBC derived microparticle proteomes of SCD and control blood. This seminar, will also focus on proteomic differences between Microparticles derived from wildtype and SCD transgenic mouse models. Finally, we extended this study to characterize the impact of hydroxyurea treatment. The goal of these LBVB studies is to determine the global impact of HbS oxidation on the proteome (relative to wildtype control blood) and to access how hydroxyurea treatment changes the overall proteome associated with SCD. The results from this seminar will ultimately provide new mechanistic insight into molecular details (at the proteome level) of SCD and potential hydroxyurea treatment.

Seminars will be webcast online at and available on the
Proteomics Interest Group website as an archived presentation unless otherwise noted.

NIH Special Interest Groups home page NIH Home Page

This site was updated on March 14th, 2018. Please contact Renee Olano at olanol(at) with questions or suggestions.